Author

H. Syed

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:genetic perturbation / CRISPR· 2 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

T. Bagci-Onder· 3 shared A. C. Aksu· 2 shared A. Cingoz· 2 shared A. P. Cribbs· 2 shared B. Cevatemre· 2 shared B. Dedeoglu· 2 shared C. ACILAN AYHAN· 2 shared I. Bulut· 2 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

T. Bagci-Onder

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer

O. Yedier-Bayram, A. Cingoz, E. Yilmaz, A. C. Aksu, B. Esin, N. Pinarbasi Degirmenci, A. D. Cavga, B. Dedeoglu, B. Cevatemre, H. Syed, M. Philpott, A. P. Cribbs, U. Oppermann, N. Lack, C. ACILAN AYHAN, , T. Bagci-Onder

The paper identifies BRPF1 as a key regulator of Taxol resistance in TNBC through genetic and chemical screens, showing its inhibition sensitizes resistant cells to chemotherapy.

bioRxiv · Apr 16, 2024Cancer Biology

Exploiting Epigenetic Targets to Overcome Taxane Resistance in Prostate Cancer

B. Cevatemre, I. Bulut, B. Dedeoglu, A. Isiklar, H. Syed, O. Yedier Bayram, T. Bagci-Onder, C. Acilan Ayhan

This study identifies BRPF reader proteins and epigenetic regulators as targets to overcome taxane resistance in prostate cancer by reversing ABCB1-mediated efflux and restoring taxane susceptibility.

bioRxiv · Aug 10, 2023Cancer Biology

Mouse mammary tumor virus is implicated in severity of colitis and dysbiosis in the IL-10-/- mouse model of inflammatory bowel disease

H. Armstrong, M. Rahbari, H. Park, D. Sharon, A. Thiesen, N. Hotte, N. Sun, H. Syed, H. Abofayed, W. Wang, K. Madsen, E. Wine, A. Mason

This study investigates the role of mouse mammary tumor virus (MMTV) in colitis and dysbiosis in IL-10-/- mice, finding that MMTV contributes to disease severity and that antiretroviral therapy reduces MMTV load and improves symptoms.

bioRxiv · Jan 26, 2023Microbiology

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology